Halozyme Therapeutics and Catalyst Pharmaceuticals are seeing double-digit revenue and EPS growth. Both companies have low debt and potential for acquisitions, with valuations below sector average. Halozyme focuses on drug-delivery systems and royalties, while Catalyst specializes in rare disease treatments with high margins. Both are profitable, with strong growth potential in 2026.

Read more at Yahoo Finance: 2 Under-the-Radar Biotech Stocks Set to Boom in 2026